SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Recent discussions around DJT are buzzing with political undertones, touching on topics from border security and immigration to trade relations. Community sentiment appears divided, with some users expressing concerns about potential impacts on American ranchers and farmers. The stock's performance and broader implications of political events remain central to the conversation.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending, with community members discussing its price action and potential. There is chatter about exchange-traded funds (ETFs), with Fidelity recently listing Solana. Some users are highlighting Solana's ecosystem and potential for future growth.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its commitment to building and developing the project, highlighting its staking on BiFinance and Broke Perspective media platform. Despite market dips, the community emphasizes its resilience, ongoing development, and the pursuit of long-term growth on the Solana blockchain. Talk centers on the potential for a resurgence in price action and a push towards a token supply burn at 2500 watchers.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Canada, Mexico, Suriname, Argentina, Peru, Australia, Papua New Guinea, Ghana, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is trending as investors digest recent earnings and production updates, with community sentiment split between disappointment in the new CEO's presentation and optimism about the company's long-term value given current gold prices. Discussions revolve around whether the recent price action represents a buying opportunity or a sign of deeper issues, with some suggesting potential manipulation to drive down call options. The broader context includes rising gold prices and speculation about potential mergers within the mining sector.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

$BALLIN is gaining attention, with community members highlighting its availability on Phantom Wallet and touting potential gains. The conversation centers around 'bags,' 'moonshots,' and 'rocket mode,' with many suggesting it's an opportune time to get in early. Some users are expressing concerns and caution.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending due to a sharp rebound after a significant decline, with community members debating whether the bottom has been reached and discussing potential catalysts like earnings and partnerships. The stock's connection to the AI infrastructure boom and recent news regarding accelerated power hookups for data centers are also fueling interest. Bullish investors are highlighting the company's long-term potential and the increasing demand for AI infrastructure.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its potential role in AI infrastructure, particularly following a $200M deal with Palantir that has sparked optimism. Community members are focused on Lumen's fiber optic network and data center connectivity, anticipating significant growth and a possible turnaround for the company. Bullish sentiment is building, with many expressing confidence in Lumen's long-term prospects within the evolving AI landscape.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USD Coin is trending amid discussions around stablecoin regulation and increasing adoption, particularly on Solana. Community members are highlighting its use in remittances, DeFi, and as a hedge against inflation in emerging markets. The meme coin BrokeCoin is also garnering attention within the USDC conversation.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers (DECK) is trending due to a significant after-hours selloff despite the company reporting better-than-expected earnings, with the community debating whether the dip is a buying opportunity or a sign of deeper issues. The cautious outlook and slowing international growth are raising concerns, while some investors point to the company's buyback program and potential for recovery. Discussions also include the impact of tariffs and comparisons to other companies in the apparel and footwear sector.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending amid discussions around trade relations, particularly Trump's stance on Canada, and anticipation of upcoming CPI data which is expected to be a market-moving event. Community sentiment appears mixed, with some expressing skepticism about the market's sustained rally and potential impacts of the government shutdown. Overall, traders are closely watching for signals that could influence the Federal Reserve's next move.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc. (Fulcrum or the Company) (NASDAQ: FULC). Investors who...

FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm! FULC INVESTOR ALERT: Bronstein...

FULC Stock Falls as Muscle Disorder Study Misses Primary Goal

Shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) plunged 61.1% on Sept.
read more...

Breaking Down Fulcrum Therapeutics: 7 Analysts Share Their Views

Latest Ratings for FULC
 DateFirmActionFromTo Mar 2022OppenheimerInitiates Coverage OnOutperform Aug 2021HC Wainwright & Co.MaintainsBuy Aug 2021SVB LeerinkMaintainsOutperform
 View More Analyst...

Shares of Fulcrum Therapeutics, Inc. (FULC) plummeted nearly 70% on Thursday, making it the biggest loser across U.S. exchanges, after the company announced the failure of its drug candidate aimed at treating a rare muscle disorder .The Phase 3 REACH trial for losmapimod, an experimental drug aimed at treating facioscapulohumeral muscular dystrophy (FSHD), did not meet its primary or secondary endpoints.FSHD, a rare genetic disorder that causes muscle weakness and wasting, reportedly affects about four in 100,000 individuals.Losmapimod was positioned to become the first approved therapy for this progressive muscle-wasting condition, but the trial’s failure marks a significant setback for Fulcrum and its ambitions.The trial’s failure is a particularly harsh blow given Sanofi’s recent $80 million bet on losmapimod just four months ago. The licensing deal carried hopes that late-stage success could propel the p38 inhibitor into a first-of-its-kind treatment for FSHD.Sanofi’s U.S.-listed shares were down 1.3% on the Nasdaq following the news.With $273.8 million in cash and equivalents, Fulcrum plans to shift focus to its remaining pipeline, led by pociredir, a Phase 1-stage drug for sickle cell disease that aims to increase fetal hemoglobin expression.However, the outlook remains bleak as analysts slashed their ratings and price targets on the stock.Stifel downgraded Fulcrum to ‘Hold’ from ‘Buy’, cutting its price target to $3 from $22, citing the “logical” but “disappointing” decision to discontinue losmapimod development.BofA dropped its rating to ‘Underperform’ from ‘Neutral’ and reduced its price target to $2 from $10.Leerink downgraded the stock to ‘Market Perform’ from ‘Outperform’ with a price target of $4, down from $16, pointing to high stakes and a lack of approved therapies for FSHD.Retail sentiment on Stocktwits turned sharply negative, to ‘extremely bearish’ (17/100), accompanied by increased message volume.<figure class="image"><a href="https://stocktwits.com/symbol/FULC"><img style="aspect-ratio:1314/308;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/FULC_retail_sentiment_and_message_volume_scores_Sep_12_11b09f649a.png" alt="FULC retail sentiment and message volume scores Sep 12.png" width="1314" height="308"></a><figcaption>FULC retail sentiment and message volume scores Sep 12</figcaption></figure>One user lamented, “$FULC biggest risky play in a long time turned into my biggest loss in a long time. Sorry folks.”<stembedurl>https://stocktwits.com/RonIsWrong/message/585814681</stembedurl>Another bearish watcher predicted further declines, stating, “$FULC they have nothing else in the pipeline, going to 1.”<stembedurl>https://stocktwits.com/petoss/message/585822022</stembedurl>FULC stock has lost more than half of its value this year.Read next: <a href="https://stocktwits.com/news/markets/equity/berkshire-stock-falls-after-ajit-jain-slashes-stake/c7zxwMbR5T">Berkshire Hathaway Shares Dip After Insurance Chief Ajit Jain Slashes Stake In Firm By Over 50%: Retail Holds Strong</a>

Top Wall Street Loser Fulcrum Therapeutics Drags Retail Sentiment To Ground After Drug Trial Fails, Analysts Slash Ratings

Losmapimod was positioned to become the first approved therapy for a rare muscle-wasting condition, but the trial’s failure marks a significant setback for Fulcrum and its ambitions.

Equity

FULC Investors Have Opportunity to Join Fulcrum Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. (Fulcrum or the Company) (NASDAQ...

Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial

Fulcrum Therapeutics stock drops after Phase 3 REACH trial of losmapimod flops in Facioscapulohumeral Muscular Dystrophy. The company consider suspending the program.
read more...

Futures Gain As Post-Nvidia Tech Rally Goes Global, ECB Cuts

Futures Gain As Post-Nvidia Tech Rally Goes Global, ECB Cuts

 Futures are trading higher ahead of today's PPI report, extending on yesterday's post-NVDA rebound momentum, as a rally that...

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

Current Price	$8.95
Prev Close	$9.04
Open	$9.04
Dividend Yield	0.00%
50-Day Moving Average	$7.89
Beta	1.52
Avg. Volume	519,061.57
PE Ratio	-7.37

52-Week High	$9.89
52-Week Low	$2.32
Market Capitalization	$484.12M
EPS (Annual)	-$0.1569
Price to Book	2.26
Revenue Per Employee	$1.78M
Enterprise Value/EBITDA	N/A

FULC
Fulcrum Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FULC News

FULCFulcrum Therapeutics Inc